DTL Partner ENPICOM and Glycostem receive MIT Zuid subsidy to support their R&D partnership project of over half a million euro to develop technology to predict the outcome of an NK-cell-based immunotherapy treatment.
On December 6, DTL partner ENPICOM B.V. and Glycostem Therapeutics BV, announced that their joint MIT Zuid R&D partnership subsidy has been granted. The aim of the collaboration is to develop technology to predict the outcome of an NK-cell-based immunotherapy treatment in patients with incurable locally advanced or metastatic solid tumors, for which there is no standard therapy.
